Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
25 "Hee Sook Park"
Filter
Filter
Article category
Keywords
Publication year
Authors
Original Articles
Circulating Plasma Biomarkers for TSU-68, an Oral Antiangiogenic Agent, in Patients with Metastatic Breast Cancer
Changhoon Yoo, Sung-Bae Kim, Jungsil Ro, Seock-Ah Im, Young-Hyuck Im, Jee Hyun Kim, Jin-Hee Ahn, Kyung Hae Jung, Hong Suk Song, Seok Yun Kang, Hee Sook Park, Hyun-Cheol Chung
Cancer Res Treat. 2016;48(2):499-507.   Published online July 14, 2015
DOI: https://doi.org/10.4143/crt.2015.089
AbstractAbstract PDFPubReaderePub
Purpose
This study analyzed the role of plasma biomarkers for TSU-68 in a previous phase II trial comparing TSU-68 plus docetaxel and docetaxel alone in patients with metastatic breast cancer.
Materials and Methods
A total of 77 patients were eligible for this study (38 in the TSU-68 plus docetaxel arm and 39 in the docetaxel alone arm). Blood samples were collected prior to the start of each cycle, and vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF)- AA, -AB, -BB, fibroblast growth factor, M30, C-reactive protein (CRP), and interleukin 6 (IL-6) levels were measured using enzyme linked immunosorbent assay. The primary endpoint was progression-free survival (PFS).
Results
In patients with baseline PDGF-AA ≥ median, median PFS was significantly worse in the TSU-68 plus docetaxel group than in the docetaxel alone group (5.4 months vs. 13.7 months, p=0.049), while a trend toward a PFS benefit was observed in those with baseline PDGF-AA < median (9.7 months vs. 4.0 months, p=0.18; p for interaction=0.03). In the TSU-68 plus docetaxel group, PFS showed significant association with fold changes in CRP (p=0.001), IL-6 (p < .001), PDGF-BB (p=0.02), and VEGF (p=0.047) following the first treatment cycle.
Conclusion
Baseline PDGF-AA levels and dynamics of VEGF, PDGF-BB, CRP, and IL-6 levels were predictive for the efficacy of TSU-68.
  • 11,619 View
  • 112 Download
Close layer
A Randomized Double-Blind, Double-Dummy, Multicenter Trial of Azasetron versus Ondansetron to Evaluate Efficacy and Safety in the Prevention of Delayed Nausea and Vomiting Induced by Chemotherapy
Hee Yeon Lee, Hoon-Kyo Kim, Kyung Hee Lee, Bong-Seog Kim, Hong Suk Song, Sung Hyun Yang, Joon Hee Kim, Yeul Hong Kim, Jong Gwang Kim, Sang-We Kim, Dong-Wan Kim, Si-Young Kim, Hee Sook Park
Cancer Res Treat. 2014;46(1):19-26.   Published online January 15, 2014
DOI: https://doi.org/10.4143/crt.2014.46.1.19
AbstractAbstract PDFPubReaderePub
PURPOSE
This study was conducted to evaluate the efficacy and safety of azasetron compared to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting.
MATERIALS AND METHODS
This study was a multi-center, prospective, randomized, double-dummy, double-blind and parallel-group trial involving 12 institutions in Korea between May 2005 and December 2005. A total of 265 patients with moderately and highly emetogenic chemotherapy were included and randomly assigned to either the azasetron or ondansetron group. All patients received azasetron (10 mg intravenously) and dexamethasone (20 mg intravenously) on day 1 and dexamethasone (4 mg orally every 12 hours) on days 2-4. The azasetron group received azasetron (10 mg orally) with placebo of ondansetron (orally every 12 hours), and the ondansetron group received ondansetron (8 mg orally every 12 hours) with placebo of azasetron (orally) on days 2-6.
RESULTS
Over days 2-6, the effective ratio of complete response in the azasetron and ondansetron groups was 45% and 54.5%, respectively (95% confidence interval, -21.4 to 2.5%). Thus, the non-inferiority of azasetron compared with ondansetron in delayed chemotherapy-induced nausea and vomiting was not proven in the present study. All treatments were well tolerated and no unexpected drug-related adverse events were reported. The most common adverse events related to the treatment were constipation and hiccups, and there were no differences in the overall incidence of adverse events.
CONCLUSION
In the present study, azasetron showed inferiority in the control of delayed chemotherapy-induced nausea and vomiting compared with ondansetron whereas safety profiles were similar between the two groups.

Citations

Citations to this article as recorded by  
  • Influence of ABCB1 genetic polymorphisms on the antiemetic response to ondansetron-based medication for cisplatin-based chemotherapy in South Indian cancer patients in a tertiary care hospital
    Ayyar Porkodi, Deepak Gopal Shewade, Goud Alladi Charanraj
    Current Issues in Pharmacy and Medical Sciences.2023; 36(3): 129.     CrossRef
  • Hiccups in Cancer Patients Receiving Chemotherapy: A Cross-Sectional Study
    Mevlüde Ergen, Fatma Arikan, Rüya Fırat Çetin
    Journal of Pain and Symptom Management.2021; 62(3): e85.     CrossRef
  • A Fast and Validated HPLC Method for the Simultaneous Analysis of Five 5-HT3 Receptor Antagonists via the Quantitative Analysis of Multicomponents by a Single Marker
    Fuchao Chen, Baoxia Fang, Peng Li, Sicen Wang, Amr M. Mahmoud
    International Journal of Analytical Chemistry.2021; 2021: 1.     CrossRef
  • Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis
    Vanessa Piechotta, Anne Adams, Madhuri Haque, Benjamin Scheckel, Nina Kreuzberger, Ina Monsef, Karin Jordan, Kathrin Kuhr, Nicole Skoetz
    Cochrane Database of Systematic Reviews.2021;[Epub]     CrossRef
  • Effectiveness of Steroid Rotation in a Japanese Patient with Hiccups Caused by Dexamethasone: a Case Report
    Hiroki Hosokawa, Hideaki Shimoda, Takayuki Ishii
    YAKUGAKU ZASSHI.2019; 139(4): 647.     CrossRef
  • Stability of azasetron-dexamethasone mixture for chemotherapy-induced nausea and vomiting administration
    Bao-Xia Fang, Fu-Chao Chen, Dan Zhu, Jun Guo, Lin-Hai Wang
    Oncotarget.2017; 8(63): 106249.     CrossRef
  • Gender Differences in Hiccup Patients: Analysis of Published Case Reports and Case-Control Studies
    Gyeong-Won Lee, Rock Bum Kim, Se Il Go, Hyun Seop Cho, Seung Jun Lee, David Hui, Eduardo Bruera, Jung Hun Kang
    Journal of Pain and Symptom Management.2016; 51(2): 278.     CrossRef
  • Cheaper Options in the Prevention of Chemotherapy-Induced Nausea and Vomiting
    Bishal Gyawali, Bishesh Sharma Poudyal, Mahesh Iddawela
    Journal of Global Oncology.2016; 2(3): 145.     CrossRef
  • Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review
    K. Jordan, F. Jahn, M. Aapro
    Annals of Oncology.2015; 26(6): 1081.     CrossRef
  • 11,996 View
  • 66 Download
  • 8 Web of Science
  • 9 Crossref
Close layer
Src Family Kinase Inhibitor PP2 Has Different Effects on All-Trans-Retinoic Acid or Arsenic Trioxide-Induced Differentiation of an Acute Promyelocytic Leukemia Cell Line
Suk-Gu Yoon, Hee-Jeong Cheong, Sook-Ja Kim, Kyoung Ha Kim, Sang-Cheol Lee, Namsu Lee, Hee Sook Park, Jong-Ho Won
Cancer Res Treat. 2013;45(2):126-133.   Published online June 30, 2013
DOI: https://doi.org/10.4143/crt.2013.45.2.126
AbstractAbstract PDFPubReaderePub
PURPOSE
Leukemic promyelocytes have the unique ability to undergo differentiation after exposure to retinoic acid and both differentiation and apoptosis after exposure to arsenic trioxide (ATO). Recent studies have shown that inhibition of Src family kinases (SFKs) resulted in enhancement of retinoic acid-induced myeloid differentiation.
MATERIALS AND METHODS
In this study, we investigated the question of whether the SFK inhibitor PP2 enhanced the differentiation of NB4 cells when combined with ATO as well as when combined with all-trans-retinoic acid (ATRA). In addition, we attempted to determine the difference in retinoic acid-induced gene expression between cells treated with PP2 in combination with ATRA and in combination with ATO.
RESULTS
SFK inhibitor PP2 induced significant enhancement of ATRA- or ATO-induced differentiation of NB4 cells. A significantly stronger synergistic effect was observed when PP2 was combined with ATRA than when combined with ATO. Flow cytometric analysis demonstrated a significant increase in CD11b-positive granulocytes up to 60.73% and 31.58%, respectively. These results were confirmed by nitroblue tetrazolium staining. These effects were not related to apoptosis. Results of Annexin-V-fluorescein staining revealed that PP2 combined with ATRA or PP2 combined with ATO did not induce apoptosis in NB4 cells. Retinoic acid-induced gene expression was different in both groups. Intercellular adhesion molecule-1 expression showed a significant increase in cells treated with PP2 in combination with ATRA, whereas cathepsin D expression showed a significant increase in cells treated with PP2 in combination with ATO.
CONCLUSION
Our data showed that SFK inhibitor PP2 enhanced acute promyelocytic leukemia cell differentiation when combined with either ATRA or ATO with difference in activation of retinoic acid-induced genes.

Citations

Citations to this article as recorded by  
  • An overview of arsenic trioxide-involved combined treatment algorithms for leukemia: basic concepts and clinical implications
    Yanan Jiang, Xiuyun Shen, Fengnan Zhi, Zhengchao Wen, Yang Gao, Juan Xu, Baofeng Yang, Yunlong Bai
    Cell Death Discovery.2023;[Epub]     CrossRef
  • Integrated bioinformatics analysis and network pharmacology to explore the potential mechanism of Patrinia heterophylla Bunge against acute promyelocytic leukemia
    Liya Feng, Sha Zhu, Jian Ma, Yali Hong, Meixia Wan, Qian Qiu, Hongjing Li, Juan Li
    Medicine.2023; 102(40): e35151.     CrossRef
  • Serum levels of FAK and some of its effectors in adult AML: correlation with prognostic factors and survival
    Mona G. El-Sisi, Sara M. Radwan, Alia M. Saeed, Hala O. El-Mesallamy
    Molecular and Cellular Biochemistry.2021; 476(5): 1949.     CrossRef
  • O-GlcNAc homeostasis contributes to cell fate decisions during hematopoiesis
    Zhen Zhang, Matthew P. Parker, Stefan Graw, Lesya V. Novikova, Halyna Fedosyuk, Joseph D. Fontes, Devin C. Koestler, Kenneth R. Peterson, Chad Slawson
    Journal of Biological Chemistry.2019; 294(4): 1363.     CrossRef
  • Src family kinases and their role in hematological malignancies
    Matthew Ku, Meaghan Wall, Ruth N. MacKinnon, Carl R. Walkley, Louise E. Purton, Constantine Tam, David Izon, Lynda Campbell, Heung-Chin Cheng, Harshal Nandurkar
    Leukemia & Lymphoma.2015; 56(3): 577.     CrossRef
  • Hematopoietic cell kinase (HCK) as a therapeutic target in immune and cancer cells
    Ashleigh R. Poh, Robert J.J. O’Donoghue, Matthias Ernst
    Oncotarget.2015; 6(18): 15752.     CrossRef
  • Src family kinase inhibitor PP2 enhances differentiation of acute promyelocytic leukemia cell line induced by combination of all-trans-retinoic acid and arsenic trioxide
    Yun Seok Jung, Hee-Jeong Cheong, Sook-Ja Kim, Kyoung Ha Kim, Namsu Lee, Hee Sook Park, Jong-Ho Won
    Leukemia Research.2014; 38(8): 977.     CrossRef
  • 11,453 View
  • 64 Download
  • 7 Crossref
Close layer
Clinical Outcome of Gastric Cancer Patients with Bone Marrow Metastases
Ji Yeon Kwon, Jina Yun, Han Jo Kim, Kyoung-Ha Kim, Se-Hyung Kim, Sang-Cheol Lee, Hyun Jung Kim, Sang Byung Bae, Chan Kyu Kim, Nam Su Lee, Kyu Taek Lee, Seong Kyu Park, Jong-Ho Won, Dae Sik Hong, Hee Sook Park
Cancer Res Treat. 2011;43(4):244-249.   Published online December 27, 2011
DOI: https://doi.org/10.4143/crt.2011.43.4.244
AbstractAbstract PDFPubReaderePub
PURPOSE
The prognosis of gastric cancer patients with bone marrow metastases is extremely poor. The current study was conducted to evaluate the clinical outcomes of advanced gastric cancer patients with bone marrow metastases.
MATERIALS AND METHODS
We retrospectively reviewed the medical records of 26 advanced gastric cancer patients with bone marrow metastases who were treated at Soonchunhyang University Hospital between September 1986 and February 2009.
RESULTS
The median age was 46 years (range, 24 to 61 years). All patients had poorly differentiated adenocarcinoma, including 17 signet ring cell carcinomas. The majority of the patients had thrombocytopenia, anemia, and elevated lactate dehydrogenase levels. Sixteen patients (61.5%) received palliative chemotherapy (median, 4 cycles; range, 1 to 13 cycles). The median overall survival after detection of bone marrow metastases for the cohort of patients was 37 days (95% confidence interval, 12.5 to 61.5 days). The median overall survival after detection of bone marrow involvement was 11 days in the best supportive care group (range, 2 to 34 days) and 121 days (range, 3 to 383 days) in the palliative chemotherapy group (p<0.001). The causes of death were tumor progression (11 patients, 45%), brain hemorrhage (6 patients, 25%), infection (5 patients, 21%), and disseminated intravascular coagulation (1 patient, 4%). There were no chemotherapy-related deaths.
CONCLUSION
Palliative chemotherapy could be considered in advanced gastric cancer patients with bone marrow metastases as a treatment option.

Citations

Citations to this article as recorded by  
  • Long-term survival of a patient with gastric cancer with bone marrow metastasis receiving S-1 plus oxaliplatin beyond three years: a case report and literature review
    Hirotaka Suto, Yumiko Inui, Atsuo Okamura
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • Comprehensive review of solid tumor bone marrow metastasis
    Lanxin Zhang, Fengxi Chen, Lingzhi Xu, Ning Li, Qiping Zhuo, Yijin Guo, Xueqing Wang, Meijie Wen, Zuowei Zhao, Man Li
    Critical Reviews in Oncology/Hematology.2024; 194: 104248.     CrossRef
  • Mechanism and clinical progression of solid tumors bone marrow metastasis
    Ruohan Yang, Lin Jia, Jiuwei Cui
    Frontiers in Pharmacology.2024;[Epub]     CrossRef
  • Is Bone Marrow Metastasis in Gastric Cancer Adequate for Best Supportive Care Decisions? Or is There Still a Chance?
    Berkan Karabuğa, Ergin Aydemir, Fatih Yıldız, Necati Alkış
    Acta Haematologica Oncologica Turcica.2024;[Epub]     CrossRef
  • Case Report: Prompt Response to Savolitinib in a Case of Advanced Gastric Cancer With Bone Marrow Invasion and MET Abnormalities
    Wen Ye, Liping He, Lei Su, Zhousan Zheng, Meilin Ding, Sheng Ye
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Bone Metastasis From Gastric Adenocarcinoma—What Are the Risk Factors and Associated Survival? A Large Comprehensive Population-Based Cohort Study
    Lei Huang, Yajie Zhao, Yan Shi, Weiguo Hu, Jun Zhang
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Gastric Cancer With Multiple Bone Metastases: An Uncommon Primary Presentation
    João Barbosa-Martins, Salomé Marques, Olinda Miranda, Bárbara Lima, Jorge Cotter
    Cureus.2022;[Epub]     CrossRef
  • Docetaxel and Fluorouracil as First-Line Therapy for Gastric Cancer with Bone Marrow Metastasis and Disseminated Intravascular Coagulation
    Zhai Xiaohui, Li Shanshan, Cao Taiyuan, Du Ge, Yu Hongen, Shi Lishuo, Lin Xiaoru, Hong Wanjia, Xiao Jian
    Future Oncology.2022; 18(35): 3875.     CrossRef
  • The influence of serum sodium concentration on prognosis in patients with urothelial carcinoma treated by radical cystectomy
    Yan Zhang, Zuojun Wang, Xue Yang, Qingchun Zhao, Long He
    Medicine.2022; 101(52): e31973.     CrossRef
  • Access to Palliative Care Services and Clinical Outcomes of Patients With Solid Malignancy-Associated Myelophthisis in a Resource-Limited Setting
    Cesar Vargas-Serafin, Aldo A. Acosta-Medina, Kevin Teran-De-la-Sancha, Jesus Delgado-de-la-Mora, María T. Bourlon, Christianne Bourlon
    American Journal of Hospice and Palliative Medicine®.2021; 38(8): 932.     CrossRef
  • Disseminated Bone Marrow Carcinomatosis Due to Malignant Melanoma of Unknown Primary Origin
    Kotaro Matsumoto, Kentaro Kikuchi, Tomohiro Kikuyama, Go Saito, Takako Adachi, Ayako Watanabe, Hiromichi Tsunashima, Takayuki Tsujikawa, Ken Sato, Shinpei Doi
    Internal Medicine.2021; 60(21): 3469.     CrossRef
  • Survival Outcomes and Treatment Decision by Human Papillomavirus Status Among Patients With Stage IVC Head and Neck Squamous Cell Carcinoma
    Ping Zhou, Yi-Feng Yu, Chen-Lu Lian, Jun Wang, Ren-Gong Zhuo, San-Gang Wu
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Gastric Signet Ring Cell Carcinoma with Metastasis to the Bone and Bone Marrow in a Patient with 12-Year-Disease-Free Interval and Unusually Long Survival Time
    Hyung Woo Kim, Mi Jin Gu, Jong Ho Lee
    Laboratory Medicine Online.2021; 11(4): 305.     CrossRef
  • Signet-ring cells in the bone marrow as an indication of cryptic metastasis of breast carcinoma
    Shuang Ma, Bruce D. Leckey Jr, Wan-Lin Zhang, Hong-Tao Xu, Lian-He Yang, Endi Wang
    Medicine.2019; 98(11): e14883.     CrossRef
  • Weighing the prognostic role of hyponatremia in hospitalized patients with metastatic solid tumors: the HYPNOSIS study
    Giovanni Fucà, Luigi Mariani, Salvatore Lo Vullo, Giulia Galli, Rossana Berardi, Massimo Di Nicola, Claudio Vernieri, Daniele Morelli, Katia Dotti, Ilaria Fiordoliva, Silvia Rinaldi, Cecilia Gavazzi, Filippo Pietrantonio, Marco Platania, Filippo de Braud
    Scientific Reports.2019;[Epub]     CrossRef
  • Malignant Pleural Mesothelioma with Bone Marrow Metastases
    Hiroaki Ihara, Norihiro Harada, Naoko Shimada, Koichiro Kanamori, Takuo Hayashi, Toshimasa Uekusa, Kazuhisa Takahashi
    Internal Medicine.2018; 57(17): 2541.     CrossRef
  • An unusual hematological presentation of gastric adenocarcinoma
    Hendra Koncoro, Eddy Setijoso, Findy Prasetiawaty, Maisie ME Johan, Renaningtyas Tambun
    Gastroenterology & Hepatology: Open Access.2018;[Epub]     CrossRef
  • Clinical outcome of 30 patients with bone marrow metastases
    Min Hang Zhou, Zhi Hong Wang, Hong Wei Zhou, Mo Liu, Yong Jian Gu, Jun Zhong Sun
    Journal of Cancer Research and Therapeutics.2018; 14(Suppl 2): S512.     CrossRef
  • Recurrent gastric cancer metastasizing to the bone marrow: A case report of a rare presentation
    Ernest Fonocho, Nail Aydin, Srini Reddy, Subhasis Misra
    International Journal of Surgery Case Reports.2017; 37: 165.     CrossRef
  • Clinical Outcomes of Endoscopic Hemostasis for Bleeding in Patients with Unresectable Advanced Gastric Cancer
    In Ji Song, Hyun Ju Kim, Ji Ae Lee, Jun Chul Park, Sung Kwan Shin, Sang Kil Lee, Yong Chan Lee, Hyunsoo Chung
    Journal of Gastric Cancer.2017; 17(4): 374.     CrossRef
  • Generalized high bone mineral density on bone density scanning: a case of gastric carcinoma with bone metastasis
    Pianpian Fan, Qin Wang, Chunyan Lu, Decai Chen
    Postgraduate Medicine.2017; 129(2): 299.     CrossRef
  • A case of disseminated carcinomatosis of the bone marrow originating from gastric cancer 3 years after intraperitoneal chemotherapy against peritoneal carcinomatosis
    Takayuki Okuno, Hironori Yamaguchi, Joji Kitayama, Hironori Ishigami, Takeshi Nishikawa, Junichiro Tanaka, Toshiaki Tanaka, Tomomichi Kiyomatsu, Keisuke Hata, Hiroaki Nozawa, Kazushige Kawai, Shinsuke Kazama, Soichiro Ishihara, Eiji Sunami, Toshiaki Watan
    World Journal of Surgical Oncology.2016;[Epub]     CrossRef
  • Pathological findings in a case of bone marrow carcinosis due to gastric cancer complicated by disseminated intravascular coagulation and thrombotic microangiopathy
    Yoshinobu Seki, Kunihiko Wakaki
    International Journal of Hematology.2016; 104(4): 506.     CrossRef
  • Endoscopic Management of Tumor Bleeding from Inoperable Gastric Cancer
    Young-Il Kim, Il Ju Choi
    Clinical Endoscopy.2015; 48(2): 121.     CrossRef
  • An Unusual Case of Gastric Cancer with Bone Marrow Metastases and Embolic Phenomena as Initial Presentation
    Harjot Kaur, Appalanaidu Sasapu, Jeanette Ramos, Rangaswamy Govindarajan
    Journal of Gastrointestinal Cancer.2015; 46(4): 413.     CrossRef
  • Development and Validation of a Prognostic Score to Predict Survival in Adult Patients With Solid Tumors and Bone Marrow Metastases
    Wen-Chi Chou, Kun-Yun Yeh, Meng-Ting Peng, Jen-Shi Chen, Hung-Ming Wang, Yung-Chang Lin, Chien-Ting Liu, Shau-Hsuan Li, Pei-Hung Chang, Cheng-Hsu Wang, Ping-Tsung Chen, Yu-Shin Hung, Chang-Hsien Lu
    Medicine.2015; 94(23): e966.     CrossRef
  • Her-2 Positive Gastric Cancer Presented with Thrombocytopenia and Skin Involvement: A Case Report
    Deniz Arslan, Mukremin Uysal, Ali Murat Tatlı, Seyda Gunduz, Sema Sezgin Goksu, Cumhur İbrahim Başsorgun, Hasan Senol Coskun, Hakan Bozcuk, Burhan Savaş
    Case Reports in Oncological Medicine.2014; 2014: 1.     CrossRef
  • Gastric Carcinoma with Bone Marrow Metastasis: A Case Series
    Ahmet Şiyar Ekinci, Öznur Bal, Tahsin Özatlı, İbrahim Türker, Onur Eşbah, Ayşe Demirci, Burçin Budakoğlu, Ülkü Yalçıntaş Arslan, Emrah Eraslan, Berna Öksüzoğlu
    Journal of Gastric Cancer.2014; 14(1): 54.     CrossRef
  • Gastric cancer with initial bone metastasis: A distinct group of diseases with poor prognosis
    Yu Jung Kim, Se Hyun Kim, Jin Won Kim, Jeong-Ok Lee, Jee Hyun Kim, Soo-Mee Bang, Jong Seok Lee, Keun-Wook Lee
    European Journal of Cancer.2014; 50(16): 2810.     CrossRef
  • Methylated TIMP-3 DNA in Body Fluids Is an Independent Prognostic Factor for Gastric Cancer
    Jiang-Liu Yu, Ping Lv, Jing Han, Xin Zhu, Lian-Lian Hong, Wang-Yu Zhu, Xin-Bao Wang, Yi-Chen Wu, Pei Li, Zhi-Qiang Ling
    Archives of Pathology & Laboratory Medicine.2014; 138(11): 1466.     CrossRef
  • Prognostic Factors in Adult Patients with Solid Cancers and Bone Marrow Metastases
    Yu-Shin Hung, Wen-Chi Chou, Tai-Di Chen, Tse-Ching Chen, Po-Nan Wang, Hung Chang, Hung-Chih Hsu, Wen-Chi Shen, Wei-Hong Cheng, Jen-Shi Chen
    Asian Pacific Journal of Cancer Prevention.2014; 15(1): 61.     CrossRef
  • Preoperative serum pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen level predicts postoperative distant metastasis in patients with non-small-cell lung cancer†
    Yumi Tanaka, Tatsuya Yoshimasu, Shoji Oura, Yoshimitsu Hirai, Mitsumasa Kawago, Masako Ikeda, Yoshitaka Okamura
    European Journal of Cardio-Thoracic Surgery.2013; 44(3): 539.     CrossRef
  • 12,919 View
  • 105 Download
  • 32 Crossref
Close layer
Efficacy and Safety of Oxaliplatin, 5-Fluorouracil, and Folinic Acid Combination Chemotherapy as First-Line Treatment in Metastatic or Recurrent Gastric Cancer
Han Jo Kim, Jun Young Eun, Young Woo Jeon, Jina Yun, Kyoung Ha Kim, Se Hyung Kim, Hyun Jung Kim, Sang-Cheol Lee, Sang Byung Bae, Chan Kyu Kim, Nam Su Lee, Kyu Taek Lee, Seong-Kyu Park, Jong-Ho Won, Dae Sik Hong, Hee Sook Park
Cancer Res Treat. 2011;43(3):154-159.   Published online September 30, 2011
DOI: https://doi.org/10.4143/crt.2011.43.3.154
AbstractAbstract PDFPubReaderePub
PURPOSE
We retrospectively determined the efficacy and safety of the combination of oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) as first-line chemotherapy for patients with metastatic or recurrent gastric cancer.
MATERIALS AND METHODS
Between January 2006 and August 2009, 39 patients with histologically-confirmed, metastatic or recurrent gastric cancer underwent chemotherapy, and the results were retrospectively investigated. The chemotherapy regimen consisted of oxaliplatin (100 mg/m2) and FA (200 mg/m2; 2-hour infusion), then 5-FU (2,400 mg/m2; 46-hour continuous infusion) every 2 weeks.
RESULTS
Thirty-nine patients received a total of 210 treatment cycles. The median number of cycles was 6 (range, 1 to 16). Of the 32 evaluable patients, zero patients achieved a complete response and 11 patients achieved a partial response (response rate, 28.2%). The median time-to-progression and overall survival were 4.3 months (95% confidence interval [CI], 2.0 to 6.5 months) and 9.8 months (95% CI, 3.5 to 16.0 months), respectively. The main hematologic toxicity was anemia, which was observed in 119 cycles (56.7%). Grade 3/4 neutropenia was observed in 32 cycles (15.2%). The main non-hematologic toxicity was constipation, which was observed in 91 cycles (46.2%). Peripheral neuropathy occurred in 71 cycles (33.8%); all cases were grade 1 or 2. No treatment-related deaths were reported.
CONCLUSION
This study showed that combination chemotherapy with oxaliplatin, 5-FU, and FA is an active and well-tolerated regimen as first-line treatment in patients with metastatic or recurrent gastric cancer.

Citations

Citations to this article as recorded by  
  • Post-Marketing Surveillance of a generic Oxaliplatin (AlvoxalⓇ) in Iranian Patients with Cancer
    Farhad Shahi, Mojtaba Gorji, Mehrdad Payandeh, Hamid Rezvani, Mohammad Vaezi, Sharareh Seifi, Alireza Baari, Reza Khalili-Dizaji, Seyed Mehdi Hashemi, Saeid Salimi, Hosein Kamranzadeh, Babak Shazad, Sina Salari, Davoud Oulad Dameshghi, Mehdi Sarkheil, Meh
    Current Therapeutic Research.2022; 96: 100657.     CrossRef
  • Quantitative proteomic analysis of oxaliplatin induced peripheral neurotoxicity
    Linlin Yang, Hua Wang, Wanting Lu, Gangqi Yang, Zian Lin, Ruibing Chen, Hongyan Li
    Journal of Proteomics.2022; 266: 104682.     CrossRef
  • Current therapeutic options for gastric adenocarcinoma
    C.R. Akshatha, Smitha Bhat, R. Sindhu, Dharini Shashank, Sarana Rose Sommano, Wanaporn Tapingkae, Ratchadawan Cheewangkoon, Shashanka K. Prasad
    Saudi Journal of Biological Sciences.2021; 28(9): 5371.     CrossRef
  • Targeting heat-shock protein 90 with ganetespib for molecularly targeted therapy of gastric cancer
    H Liu, J Lu, Y Hua, P Zhang, Z Liang, L Ruan, C Lian, H Shi, K Chen, Z Tu
    Cell Death & Disease.2015; 6(1): e1595.     CrossRef
  • Oxaliplatin induced-neuropathy in digestive tumors
    María Sereno, Gerardo Gutiérrez-Gutiérrez, César Gómez-Raposo, Miriam López-Gómez, Maria Merino-Salvador, Francisco Zambrana Tébar, Cristina Rodriguez-Antona, Enrique Casado
    Critical Reviews in Oncology/Hematology.2014; 89(1): 166.     CrossRef
  • Effect of doxorubicin, oxaliplatin, and methotrexate administration on the transcriptional activity ofBCL-2family gene members in stomach cancer cells
    Dimitra Florou, Christos Patsis, Alexandros Ardavanis, Andreas Scorilas
    Cancer Biology & Therapy.2013; 14(7): 587.     CrossRef
  • The kallikrein-related peptidase 13 (KLK13) gene is substantially up-regulated after exposure of gastric cancer cells to antineoplastic agents
    Dimitra Florou, Konstantinos Mavridis, Andreas Scorilas
    Tumor Biology.2012; 33(6): 2069.     CrossRef
  • 10,598 View
  • 59 Download
  • 7 Crossref
Close layer
Phase II Clinical Trial of Genexol(R) (Paclitaxel) and Carboplatin for Patients with Advanced Non-small Cell Lung Cancer
Han Jo Kim, Kyoung Ha Kim, Jina Yun, Se Hyung Kim, Hyun Jung Kim, Sang-Cheol Lee, Sang Byung Bae, Chan Kyu Kim, Nam Su Lee, Kyu Taek Lee, Do-Jin Kim, Seong-Kyu Park, Jong-Ho Won, Dae Sik Hong, Hee Sook Park
Cancer Res Treat. 2011;43(1):19-23.   Published online March 31, 2011
DOI: https://doi.org/10.4143/crt.2011.43.1.19
AbstractAbstract PDFPubReaderePub
PURPOSE
This phase II clinical trial was conducted to evaluate the activity and safety of a combination treatment of paclitaxel (Genexol(R)) plus carboplatin in patients with advanced non-small cell lung cancer.
MATERIALS AND METHODS
Chemotherapy-naive patients having histologically confirmed advanced or metastatic non-small cell lung cancer were enrolled. Genexol(R) was administered at 225 mg/m2 intravenous (IV) infusion over 3 hours, followed by carboplatin (area under the concentration-time curve=6) IV on day 1 every 3 weeks.
RESULTS
Twenty-eight patients were enrolled between January 2003 and January 2005. A total of 110 cycles of chemotherapy were given. The median number of chemotherapy cycles was 4. A total of 25 study patients were evaluable. On an intent-to-treat basis, there were ten partial responses (response rate 35.7%). The median time-to-progression was 3.2 months (95% confidence interval [CI], 1.5 to 4.9) and the median overall survival was 8.2 months (95% CI, 4.1 to 12.3). The main hematologic grade 3/4 toxicity was neutropenia, which was observed in 14 (50.0%) patients. The main non-hematologic toxicity was peripheral neuropathy, which was observed in 12 patients (42.9%). Grade 3/4 neuropathy occurred in 8 patients (28.6%) and three patients discontinued treatment because of neuropathy.
CONCLUSION
In this trial, the combination of Genexol(R) and carboplatin showed significant activity as first line treatment for patients with advanced or metastatic non-small cell lung cancer. However, a modest dose reduction of Genexol(R) is needed due to sensory neuropathy.

Citations

Citations to this article as recorded by  
  • Therapeutic Nanoparticles: Advantages and Toxicity
    Dr. Lata Ramrakhiani
    Indian Journal of Environment Engineering.2022; 2(1): 19.     CrossRef
  • Engineering Chimeric Receptors To Investigate the Size- and Rigidity-Dependent Interaction of PEGylated Nanoparticles with Cells
    Wei-Chiao Huang, Pierre-Alain Burnouf, Yu-Cheng Su, Bing-Mae Chen, Kuo-Hsiang Chuang, Chia-Wei Lee, Pei-Kuen Wei, Tian-Lu Cheng, Steve R. Roffler
    ACS Nano.2016; 10(1): 648.     CrossRef
  • Nanotechnology applications in thoracic surgery
    Sophie C. Hofferberth, Mark W. Grinstaff, Yolonda L. Colson
    European Journal of Cardio-Thoracic Surgery.2016; 50(1): 6.     CrossRef
  • Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release
    Nazila Kamaly, Basit Yameen, Jun Wu, Omid C. Farokhzad
    Chemical Reviews.2016; 116(4): 2602.     CrossRef
  • Novel Water-Borne Polyurethane Nanomicelles for Cancer Chemotherapy: Higher Efficiency of Folate Receptors Than TRAIL Receptors in a Cancerous Balb/C Mouse Model
    Elham Ajorlou, Ahmad Yari Khosroushahi, Hamid Yeganeh
    Pharmaceutical Research.2016; 33(6): 1426.     CrossRef
  • Reinvention of chemotherapy
    Tu Nguyen-Ngoc, Eric Raymond
    Current Opinion in Oncology.2015; 27(3): 232.     CrossRef
  • Lung Cancer Nanomedicine: Potentials and Pitfalls
    Deniz Ali Bölükbas, Silke Meiners
    Nanomedicine.2015; 10(21): 3203.     CrossRef
  • Nanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research
    Susana Patricia Egusquiaguirre, Manuela Igartua, Rosa María Hernández, José Luis Pedraz
    Clinical and Translational Oncology.2012; 14(2): 83.     CrossRef
  • Novel water-soluble polyurethane nanomicelles for cancer chemotherapy: physicochemical characterization and cellular activities
    Ahmad Yari Khosroushahi, Hossein Naderi-Manesh, Hamid Yeganeh, Jaleh Barar, Yadollah Omidi
    Journal of Nanobiotechnology.2012;[Epub]     CrossRef
  • Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress
    Twan Lammers, Fabian Kiessling, Wim E. Hennink, Gert Storm
    Journal of Controlled Release.2012; 161(2): 175.     CrossRef
  • 11,006 View
  • 68 Download
  • 10 Crossref
Close layer
Case Report
Mixed Testicular Germ Cell Tumor Presenting as Metastatic Pure Choriocarcinoma Involving Multiple Lung Metastases That Was Effectively Treated with High-dose Chemotherapy
Sang-Cheol Lee, Kyoung Ha Kim, Sung Han Kim, Nam Su Lee, Hee Sook Park, Jong-Ho Won
Cancer Res Treat. 2009;41(4):229-232.   Published online December 31, 2009
DOI: https://doi.org/10.4143/crt.2009.41.4.229
AbstractAbstract PDFPubReaderePub

Choriocarcinoma in the testis is very rare, and it represents less than 1% (0.3%) of all the testicular germ cell tumors. It is a particularly aggressive variant of non-seminoma tumor, which is characterized by a high serum β-HCG level and multiple lung metastases. The optimal management for this disease remains undefined. We report here on a case of choriocarcinoma with multiple lung metastases, and the patient has achieved continuous remission for 2 years after combination chemotherapy of BEP (bleomycin, etoposide and cisplatin) and sequential high-dose chemotherapy with autologous peripheral stem cell rescue.

Citations

Citations to this article as recorded by  
  • Testicular Mixed Germ Cell Tumor Presenting with Upper Gastrointestinal Bleeding: A Case Report
    Emilija Nikolovska Trpchevska, Beti Todorovska, Magdalena Bogdanovska Todorovska, Meri Trajkovska, Dafina Nikolova, Darko Dzambaz, Gjorgji Deriban, Fana Licoska-Josifovikj
    PRILOZI.2023; 44(2): 47.     CrossRef
  • Gastrointestinal Bleeding Secondary to Metastatic Duodenal Choriocarcinoma in a Patient with Concomitant Peptic Ulcer Disease
    Ahmed Elfiky, Asmaa Mokhtar, Mira Alsheikh, Hassan Almoussawi, Stephen Mulrooney, Haruhiko Sugimura
    Case Reports in Gastrointestinal Medicine.2021; 2021: 1.     CrossRef
  • Gastrointestinal Bleeding with Hemodynamic Repercussion due to a Gastric Metastatic Lesion of a Testicular Choriocarcinoma in a Previously Asymptomatic Young Adult
    Omar Al Salman, Fahad Malik, Shashank Trivedi, Marwah Alchalabi, Shobhana Chaudhari
    GE - Portuguese Journal of Gastroenterology.2020; 27(3): 212.     CrossRef
  • Choriocarcinomas May Be Presented with Abnormal Manifestations
    Alpaslan Tanoglu, Tolga Duzenli
    International Journal of Cancer Management.2017;[Epub]     CrossRef
  • Metastatic Testicular Choriocarcinoma: A Rare Cause of Upper GI Bleeding
    Kirsty Lowe, Jacqueline Paterson, Sharon Armstrong, Shaun Walsh, Max Groome, Craig Mowat
    ACG Case Reports Journal.2016; 3(1): 36.     CrossRef
  • Metastatic choriocarcinoma induced separate simultaneous intracerebral haemorrhages: a very rare occurrence and its novel association with Klinefelter syndrome
    Maximilian Olavi Joret, Robert M Starke, John Scotter, Peter Heppner
    BMJ Case Reports.2015; : bcr2015212777.     CrossRef
  • Contrast-Enhanced Ultrasonography of the Testes
    Ounali S. Jaffer, Paul S. Sidhu
    Ultrasound Clinics.2013; 8(4): 509.     CrossRef
  • Multiparametric ultrasonography of the testicles
    Tobias De Zordo, Daniel Stronegger, Leo Pallwein-Prettner, Chris J. Harvey, Germar Pinggera, Werner Jaschke, Friedrich Aigner, Ferdinand Frauscher
    Nature Reviews Urology.2013; 10(3): 135.     CrossRef
  • A Case of Gastrointestinal Bleeding due to Duodenal Metastasis from a Testicular Choriocarcinoma
    Magdalene Vardaros, Miral Subhani, Kaleem Rizvon, Vladimir Gotlieb, Paul Mustacchia, Lester Freedman, Vikas Garg, Jaspreet Singh, Ghulam Siddiqui
    Journal of Gastrointestinal Cancer.2013; 44(2): 234.     CrossRef
  • Unravelling mechanisms of cisplatin sensitivity and resistance in testicular cancer
    R. Koster, M.A.T.M. van Vugt, H. Timmer-Bosscha, J.A. Gietema, S. de Jong
    Expert Reviews in Molecular Medicine.2013;[Epub]     CrossRef
  • 14,832 View
  • 69 Download
  • 10 Crossref
Close layer
Original Articles
Randomized, Multicenter, Phase III Trial of Heptaplatin 1-hour Infusion and 5-Fluorouracil Combination Chemotherapy Comparing with Cisplatin and 5-Fluorouracil Combination Chemotherapy in Patients with Advanced Gastric Cancer
Kyung Hee Lee, Myung Soo Hyun, Hoon-Kyo Kim, Hyung Min Jin, Jinmo Yang, Hong Suk Song, Young Rok Do, Hun Mo Ryoo, Joo Seop Chung, Dae Young Zang, Ho-Yeong Lim, Jong Youl Jin, Chang Yeol Yim, Hee Sook Park, Jun Suk Kim, Chang Hak Sohn, Soon Nam Lee
Cancer Res Treat. 2009;41(1):12-18.   Published online March 31, 2009
DOI: https://doi.org/10.4143/crt.2009.41.1.12
AbstractAbstract PDFPubReaderePub
Purpose

Heptaplatin (Sunpla) is a cisplatin derivative. A phase IIb trial using heptaplatin resulted in a 34% response rate with mild nephrotoxicity. We conducted a randomized phase III trial of heptaplatin plus 5-FU compared with cisplatin plus 5-FU in patients with advanced gastric cancer.

Materials and Methods

One hundred seventy-four patients (heptaplatin, n=88; cisplatin, n=86) from 13 centers were enrolled. The eligibility criteria were as follows: patients with pathologically-proven adenocarcinoma, chemonaive patients, or patients who had received only single adjuvant chemotherapy, and who had a measurable or evaluable lesion. On day 1, heptaplatin (400 mg/m2) or cisplatin (60 mg/m2) was given over 1 hour with 5-FU (1 gm/m2) on days 1~5 every 4 weeks.

Results

At the time of survival analysis, the median overall survival was 7.3 months in the 5-FU + heptaplatin (FH) arm and 7.9 months in the 5-FU + cisplatin (FP) arm (p=0.24). Of the FH patients, 34.2% (complete response [CR], 1.3%; partial response [PR], 32.9%) experienced a confirmed objective response compared with 35.9% (CR 0%, PR 35.9%) of FP patients (p=0.78). The median-time-to-progression was 2.5 months in the FH arm and 2.3 months in the FP arm. The incidence of neutropenia was higher with FP (28%) than with FH (16%; p=0.06); grade 3~4 nausea and vomiting were more frequent in the FP than in the FH arm (p=0.01 and p=0.05, respectively). The incidence of increased proteinuria and creatininemia was higher with FH than with FP; however, there was no statistical difference. There were no treatment-related deaths.

Conclusion

Heptaplatin showed similar effects to cisplatin when combined with 5-FU in advanced gastric cancer patients with tolerable toxicities.

Citations

Citations to this article as recorded by  
  • The Survival and Financial Benefit of Investigator-Initiated Trials Conducted by Korean Cancer Study Group
    Bum Jun Kim, Chi Hoon Maeng, Bhumsuk Keam, Young-Hyuck Im, Jungsil Ro, Kyung Hae Jung, Seock-Ah Im, Tae Won Kim, Jae Lyun Lee, Dae Seog Heo, Sang-We Kim, Keunchil Park, Myung-Ju Ahn, Byoung Chul Cho, Hoon-Kyo Kim, Yoon-Koo Kang, Jae Yong Cho, Hwan Jung Yu
    Cancer Research and Treatment.2025; 57(1): 39.     CrossRef
  • Quantum mechanical approaches and molecular docking analysis of platinum metal-based anticancer drugs Lobaplatin and Heptaplatin targeting cancer DNA - a comparative analysis
    Madhavi Sahadevan, Mullainathan Sundaram, Karunagaran Subramanian
    Chemical Physics Letters.2024; 842: 141191.     CrossRef
  • Cisplatin Resistance in Cancer Therapy: Causes and Overcoming Strategies
    S. Shruthi, K. Bhasker Shenoy
    ChemistrySelect.2024;[Epub]     CrossRef
  • Recent Advances on Pt-Based Compounds for Theranostic Applications
    Giulia Ferrari, Ines Lopez-Martinez, Thomas Wanek, Claudia Kuntner, Diego Montagner
    Molecules.2024; 29(15): 3453.     CrossRef
  • Hallmarks of anticancer and antimicrobial activities of corroles
    Vinay K. Sharma, Yehuda G. Assaraf, Zeev Gross
    Drug Resistance Updates.2023; : 100931.     CrossRef
  • Application of Approved Cisplatin Derivatives in Combination Therapy against Different Cancer Diseases
    Dobrina Tsvetkova, Stefka Ivanova
    Molecules.2022; 27(8): 2466.     CrossRef
  • Second and third-row transition metal compounds containing benzimidazole ligands: An overview of their anticancer and antitumour activity
    Galdina V. Suárez-Moreno, Delia Hernández-Romero, Óscar García-Barradas, Óscar Vázquez-Vera, Sharon Rosete-Luna, Carlos A. Cruz-Cruz, Aracely López-Monteon, Jesús Carrillo-Ahumada, David Morales-Morales, Raúl Colorado-Peralta
    Coordination Chemistry Reviews.2022; 472: 214790.     CrossRef
  • Metalofármacos en la terapia contra el cáncer
    Elizabeth Márquez López, Esmeralda Sánchez Pavón, Rodolfo Peña Rodríguez, Delia Hernández Romero, José M. Rivera Villanueva, Raúl Colorado Peralta, David Morales Morales
    TECNOCIENCIA Chihuahua.2022; 16(3): e1010.     CrossRef
  • Platinum(IV) anticancer agents; are we en route to the holy grail or to a dead end?
    Dan Gibson
    Journal of Inorganic Biochemistry.2021; 217: 111353.     CrossRef
  • Monofunctional Platinum(II) Anticancer Agents
    Suxing Jin, Yan Guo, Zijian Guo, Xiaoyong Wang
    Pharmaceuticals.2021; 14(2): 133.     CrossRef
  • Pt(IV) Prodrugs with NSAIDs as Axial Ligands
    Daniil Spector, Olga Krasnovskaya, Kirill Pavlov, Alexander Erofeev, Peter Gorelkin, Elena Beloglazkina, Alexander Majouga
    International Journal of Molecular Sciences.2021; 22(8): 3817.     CrossRef
  • Multi-action Pt(IV) anticancer agents; do we understand how they work?
    Dan Gibson
    Journal of Inorganic Biochemistry.2019; 191: 77.     CrossRef
  • TOXview: a novel graphical presentation of cancer treatment toxicity profiles
    Lok Lam Ngai, Emil ter Veer, Héctor G. van den Boorn, E. Hugo van Herk, Jessy Joy van Kleef, Martijn G. H. van Oijen, Hanneke W. M. van Laarhoven
    Acta Oncologica.2019; 58(8): 1138.     CrossRef
  • Photoactivated platinum-based anticancer drugs
    Muhammad Imran, Wagma Ayub, Ian S. Butler, Zia-ur-Rehman
    Coordination Chemistry Reviews.2018; 376: 405.     CrossRef
  • Survival impact of post-progression chemotherapy in advanced gastric cancer: systematic review and meta-analysis
    Sakura Iizumi, Atsuo Takashima, Kentaro Sakamaki, Satoshi Morita, Narikazu Boku
    Cancer Chemotherapy and Pharmacology.2018; 81(6): 981.     CrossRef
  • An Analytics Approach to Designing Combination Chemotherapy Regimens for Cancer
    Dimitris Bertsimas, Allison O’Hair, Stephen Relyea, John Silberholz
    Management Science.2016; 62(5): 1511.     CrossRef
  • Platinum(iv) anticancer prodrugs – hypotheses and facts
    Dan Gibson
    Dalton Transactions.2016; 45(33): 12983.     CrossRef
  • Platinum(II) carboxylato complexes containing 7-azaindoles as N-donor carrier ligands showed cytotoxicity against cancer cell lines
    Pavel Štarha, Zdeněk Trávníček, Lucia Pazderová, Zdeněk Dvořák
    Journal of Inorganic Biochemistry.2016; 162: 109.     CrossRef
  • VEGF- and VEGFR2-Targeted Liposomes for Cisplatin Delivery to Glioma Cells
    Sergey A. Shein, Ilya I. Kuznetsov, Tatiana O. Abakumova, Pavel S. Chelushkin, Pavel A. Melnikov, Anna A. Korchagina, Dmitry A. Bychkov, Irina F. Seregina, Mikhail A. Bolshov, Alexander V. Kabanov, Vladimir P. Chekhonin, Natalia V. Nukolova
    Molecular Pharmaceutics.2016; 13(11): 3712.     CrossRef
  • Condensations of single DNA molecules induced by heptaplatin and its chiral isomer
    Hong-Yan Zhang, Yu-Ru Liu, Wei Li, Hui Li, Shuo-Xing Dou, Ping Xie, Wei-Chi Wang, Peng-Ye Wang
    AIP Advances.2014;[Epub]     CrossRef
  • Nanocarriers for delivery of platinum anticancer drugs
    Hardeep S. Oberoi, Natalia V. Nukolova, Alexander V. Kabanov, Tatiana K. Bronich
    Advanced Drug Delivery Reviews.2013; 65(13-14): 1667.     CrossRef
  • Progression-free survival and time to progression as surrogate markers of overall survival in patients with advanced gastric cancer: analysis of 36 randomized trials
    Kohei Shitara, Junko Ikeda, Tomoya Yokota, Daisuke Takahari, Takashi Ura, Kei Muro, Keitaro Matsuo
    Investigational New Drugs.2012; 30(3): 1224.     CrossRef
  • Cellular interactions of platinum drugs
    Ezequiel Wexselblatt, Eylon Yavin, Dan Gibson
    Inorganica Chimica Acta.2012; 393: 75.     CrossRef
  • What do we know about the reduction of Pt(IV) pro-drugs?
    Ezequiel Wexselblatt, Dan Gibson
    Journal of Inorganic Biochemistry.2012; 117: 220.     CrossRef
  • Prospective, randomized trial comparing 5-FU/LV with or without oxaliplatin as adjuvant treatment following curative resection of gastric adenocarcinoma
    X.-L. Zhang, H.-J. Shi, S.-Z. Cui, Y.-Q. Tang, M.-C. Ba
    European Journal of Surgical Oncology (EJSO).2011; 37(6): 466.     CrossRef
  • The status of platinum anticancer drugs in the clinic and in clinical trials
    Nial J. Wheate, Shonagh Walker, Gemma E. Craig, Rabbab Oun
    Dalton Transactions.2010; 39(35): 8113.     CrossRef
  • 12,096 View
  • 114 Download
  • 26 Crossref
Close layer
Effect of Arsenic Trioxide in TRAIL (Tumor Necrosis Factor-related Apoptosis Inducing Ligand)-Mediated Apoptosis in Multiple Myeloma Cell Lines
Jae Ho Byun, Young Seon Hong, Hee Jeong Cheong, Sook Ja Kim, Nam Su Lee, Jong Ho Won, Dae Sik Hong, Hee Sook Park
Cancer Res Treat. 2003;35(6):472-477.   Published online December 31, 2003
DOI: https://doi.org/10.4143/crt.2003.35.6.472
AbstractAbstract PDF
PURPOSE
The potential therapeutic application of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), in the treatment of multiple myeloma (MM), was recently proposed. However, there have been some problems with the use of TRAIL, due to the appearance of TRAIL-resistant cells in MM. The effect of arsenic trioxide (As2O3) on the rate of apoptosis induced by TRAIL was evaluated in MM cells.
MATERIALS AND METHODS
Using TRAIL-sensitive (RPMI- 8226) and TRAIL-resistant (ARH-77 and IM-9) MM cell lines, the cell viability, induction of apoptosis, and change in the caspases were examined after treatment with TRAIL alone, or in combination with various concentrations of As2O3.
RESULTS
Incubating the cell lines with As2O3 augmented the TRAIL-induced apoptosis in the MM cell lines, according to the As2O3 concentration. Apoptosis was mediated through caspase activation. When TRAIL was used alone, caspase8 was activated in the RPMI-8226 cell lines, but not in the ARH-77 and IM-9 cell lines. When As2O3 was added to TRAIL, caspase-9 was activated in the ARH-77 and IM-9 cells.
CONCLUSION
The use of As2O3, in combination with TRAIL, would help enhance the level of TRAIL-induced apoptosis, and overcome the TRAIL-resistance, in MM cells.
  • 4,114 View
  • 25 Download
Close layer
High Dose Chemotherapy and Autologous Peripheral Blood Stem Cell Transplantation for Persistent/Relapsed Ovarian Cancer
So Eun Kim, Jong Ho Won, Hyun Soo Kim, Joon Sung Park, Chan Kyu Kim, Kyu Taeg Lee, Sung Kyu Park, Seung Ho Baick, Dae Sik Hong, Hee Sook Park, Hugh Chul Kim
Cancer Res Treat. 2002;34(6):439-443.   Published online December 31, 2002
DOI: https://doi.org/10.4143/crt.2002.34.6.439
AbstractAbstract PDF
PURPOSE
High dose chemotherapy (HDC) is increasingly being used for ovarian cancer. Although early studies of autotransplantation for advanced ovarian cancer have been encouraging, most reported series were small, and no randomized trials have been reported. HDC and autologous hematopoietic stem cell transplantation were rarely performed in patients with ovarian cancer in Korea, and no results have been reported with the exception of one case report.
MATERIALS AND METHODS
We retrospectively analyzed 10 patients with refractory or relapsed ovarian cancer having received HDC and autologous peripheral blood stem cell transplantation (APBSCT), between January 1996 and September 1998, at the Soon Chun Hyang and Ajou University Hospitals.
RESULTS
Ten patients were treated with HDC and APBSCT. Six patients achieved complete response (CR) and 1 a partial response (PR), with a response rate of 70%. Three patients did not respond following mobilization chemotherapy, and failed to respond after HDC. The median duration of progression free survival (PFS) and overall survival (OS) were 6 (4~46) and 13 (3~50+) months, respectively. The median duration of OS of the responders following mobilization chemotherapy was 23 (8~50+) compared with 12 (3~18) months of the non- responders. With regard to the treatment related toxicity, 8 patients had neutropenic fevers, and bacteremia was documented in 4. The non-hematological toxicities were never life threatening, and there were no treatment related deaths.
CONCLUSION
HDC, followed by APBSCT, is well-tolerated patients with refractory or relapsed ovarian cancer, and following mobilization chemotherapy the responders survived longer than the non-responders.

Citations

Citations to this article as recorded by  
  • Analysis of chromosomal changes in serous ovarian carcinoma using high‐resolution array comparative genomic hybridization: Potential predictive markers of chemoresistant disease
    Sang Wun Kim, Jae Wook Kim, Young Tae Kim, Jae Hoon Kim, Sunghoon Kim, Bo Sung Yoon, Eun Ji Nam, Hye Yeon Kim
    Genes, Chromosomes and Cancer.2007; 46(1): 1.     CrossRef
  • 4,614 View
  • 17 Download
  • 1 Crossref
Close layer
Metastasis to the Thigh Skeletal Muscle from an Adenocarcinoma of the Duodenum
Hyo Wook Gil, Jong Ho Won, Nam Su Lee, Sang Cheol Lee, So Eun Kim, Chan Kyu Kim, Kyu Taeg Lee, Sung Kyu Park, Seung Ho Baick, Dae Sik Hong, Hee Sook Park
Cancer Res Treat. 2002;34(5):394-396.   Published online October 31, 2002
DOI: https://doi.org/10.4143/crt.2002.34.5.394
AbstractAbstract PDF
Skeletal muscle is one of the most unusual metastatic sites for any malignancy. Duodenal cancer is extremely rare, and no cases of skeletal muscle metastasis from duodenal cancer have been reported. We report here in a case of metastasis to the skeletal muscle of the left thigh from duodenal cancer. Our patient was a 47-year-old man, exhibiting a painful mass in the posterior aspect of his left thigh over a 4 month period. An imaging study, and a biopsy, revealed a duodenal adenocarcinoma metastasize to the skeletal muscle. The patient refused chemotherapy and has followed up for 4 months.
  • 4,005 View
  • 22 Download
Close layer
Randomized Controlled Open Labelled, Phase III Trials, Comparing the Efficacy between Fentas(R) and Durogesic(R) Patches in Controlling Cancer Pain: Multicenter Trial
Myung Ju Ahn, Tae June Jung, Jung Hye Choi, Mi Ran Oh, Hwi Joong Yoon, Jun Suk Kim, Chul Won Choi, Kyung Wook Hur, Dae Sik Hong, Hee Sook Park, Sung Kyu Park, Jung Ae Lee, Young Suk Park, Hyonggi Jung
Cancer Res Treat. 2002;34(3):165-169.   Published online June 30, 2002
DOI: https://doi.org/10.4143/crt.2002.34.3.165
AbstractAbstract PDF
PURPOSE
Fentanyl is a synthetic opioid and transdermal therapeutic system (TTS), designed to release the drug into the skin at a constant rate, ranging from 25 to 100 microgram/hr, for up to 3 days. For the control of chronic cancer pain, Durogesic(R) patches (Janssen Co., USA) are now widely used. Recently, the Hana Company in Korea developed a new fentanyl patch, Fentas(R) using a different method. To compare the efficacy, and safety, of the fentanyl patch manufactured in Korea (Hana Pharm. Co. Ltd), with the Durogesic(R) patch, in controlling cancer pain, we performed randomized controlled, open labelled, phase III studies. MATERIALS AND METGODS: From January 2000 to April 2001, 85 patients were enrolled, 69 of whom (42 in D arm and 43 in F arm) completed the study, and were therefore assessable for per protocol (PP) analyses.
RESULTS
There were no significant differences between the two groups in baseline characteristics, with the exception of age. The primary end point was to show the therapeutic equivalence of the two patches. In these clinical trials, the confidence interval of difference, between the test drug (Fentas(R)) and the control (Durogesic(R)), was 0.027~ +0.124 by intention to treat (ITT) analysis. Even if the upper confidence interval exceeds + 0.1, the test drug is not superior to the control drug, because the confidence interval includes 0. However, by PP analysis, the confidence interval lies exactly within +/- 0.1. Therefore, we could conclude the two patches are therapeutically equivalent. The second endpoint was the difference of visual analog scale (VAS) between the baseline and the average of three measurements after treatment. The difference in VAS was 50.44+/-10.28 for the F arm, and 44.69+/-11.00 for the D arm. By PP analysis the test drug was superior to the control (p=0.028). The rescue morphine amount was 81.21+/-124.76 for F arm and 66.19+/-115.9 for D arm, and there was no significant difference between the two groups (p=0.6063). The most common adverse effects of both fentanyl patches were nausea or vomiting (55.3%), somnolence (50.0%), constipation (39.5%), gastrointestinal discomfort (57.9%) and headaches (25.0%). In general there was no significant difference in side effects or laboratory data between the two groups.
CONCLUSION
These findings suggest that Fentas(R) patches, administered every 3 days, are effective, safe, and well tolerated for the treatment of most patients with cancer pain and is as effective or better than Durogesic(R).
  • 4,456 View
  • 33 Download
Close layer
A Comparison of the Acute Antiemetic Effect of Tropisetron with Ondansetron in Patients Receiving Cisplatin
Sung Tae Cho, Bo Kwon Hwang, Chan Kyu Kim, Bong Min Ko, Sung Han Bae, Jong Dae Bong, Cheol Woo Lee, Sung Kyu Park, Jong Ho Won, Seung Ho Baick, Dae Sik Hong, Hee Sook Park
J Korean Cancer Assoc. 1998;30(6):1240-1248.
AbstractAbstract PDF
PURPOSE
Tropisetron, a new specific 5-hydroxytryptamine3 (5-HT3) receptor antagonist, is an effective antiemetic agent in the control of chemotherapy induced emesis with a long half life and bioavailablity. We compared the efficacy and safefy of Tropisetron and ondansetron to control emesis induced by highly emetogenic chemotherapeutics (cisplatin > or = 50 mg/m(2)).
MATERIALS AND METHODS
Twenty-one patients were administered in a randomized, open, crossover study and received either tropisetron plus dexamethasone or ondansetron plus dexamethasone during two successive cycles of chemotherapy.
RESULTS
Control of acute emesis with either tropisetron or ondansetron was 100% vs 95.2%, and 80.9% vs 76.2% in control of delayed emesis. Both severity and duration of nausea showed no statistically significant difference between tropisetron and ondansetron. Poor appetite and headache were most common side effects in both groups.
CONCLUSION
There was no significant difference in efficacy for control of emesis and nausea between tropisetron and ondansetron in cisplatin-based chemotherapy.
  • 2,777 View
  • 19 Download
Close layer
Comparison of Radiation Therapy and Combined Chemotherapy and Radiation Therapy for Locally Advanced Head and Neck Cancer
Gyu Taeg Lee, Jae Ho Byun, Kwon Hwangbo, Ji Oh Mok, Eun Seuk Kim, Jong Ho Won, Seung Ho Baick, Doo Ho Choi, Dae Sik Hong, Hee Sook Park
J Korean Cancer Assoc. 1997;29(4):616-622.
AbstractAbstract PDF
PURPOSE
In locally advanced head and neck cancer, radiation therapy is currently unsatisfactory because the end result is often limited regional disease control and survival. A clinical study was carried out to compare the effectiveness between the radiation therapy and the combined chemotherapy and radiation therapy.
MATERIALS AND METHOD
Thirty-six patients with previously untreated, locally advanced squamous cell carcinoma of the head and neck were treated with radiotherapy alone and combined chemo-radiotherapy. Induction chemotherapy was administered 2~3 cycles, consisting of intravenous cisplatin (100 mg/m2 on day 1) and 5-fluorouracil (1000 mg/m2/day for 5 days as a continuous infusion) every 4 weeks followed by 7~8 weeks of radiation therapy for a total dose of 60~75 Gy. RESULTS: 1) Among 36 locally advanced head and neck cancer, 17 patients received radiation therapy alone and 19 patients received combined chemo-radiotherapy, respectively. 2) Response rate was 47% (complete response 29%, and partial response 18%) in radiation therapy group and 79% (complete response 37%, and partial response 42%) in combined chemo-radiotherapy group (p<0.05). 3) In median survival, radiation therapy group was 13 months and combined chemo- radiotherapy group was 15 months. Both groups were not significantly different (p>0.05). 4) Treatment related mortality was not noted, but the toxic effects were seen on the half cases of the both groups. Grade II toxicities were similar between the two arms.
CONCLUSION
Combined chemotherapy and radiation therapy was more effective in local control but not superior in survival than radiation therapy alone. Continuous evaluation and identification of proper sequence for the therapeutic modality is supposed to prolong the survival of patients.
  • 3,328 View
  • 13 Download
Close layer
A Case of Primary Splenic Angiosarcoma Associated with Kasabach-Merritt Syndrome
Jin Seok Jeon, Gyu Taek Lee, Ki Ju Han, Jae Ho Byun, Seung Kyu Park, Jong Ho Won, Seung Ho Baick, Dae Sik Hong, Hee Sook Park, Hae Kyung Lee, So Young Jin
J Korean Cancer Assoc. 1997;29(2):352-357.
AbstractAbstract PDF
PURPOSE
Primary malignant vascular neoplasms of the spleen are rare. It has been known that the prognosis was very poor and the splenectomy before rupture could increase survival. No effective chemotherapeutic protocol for angiosarcomas has yet to be established but patients with or without metastatic disease may be treated by chemotherapy. MATERIAL AND METHODS: We experienced a case of primary splenic angiosarcoma in a 42-year-old woman with multiple purpuric skin rashes associated with consumptive coagulopathy:the Kasabach-Merritt syndrome. The CT showed spleen is diffusely enlarged and inhomogenously enhanced with multiple metastasis in the liver. The splenectomy was done and angiosarcoma was diagnosed. We treated her with conventional combination chemotherapy and obtained partial response. For additional response, high-dose chemotherapy and stem cell rescue with autologous peripheral blood stem cell transplantation was done.
RESULT
Afer splenectomy, platelet count return to normal. The follow up abdominal CT scan after treatment showed complete disappeared multiple metastatic lesions in the both lobe of liver and the patient has continued to do well four months following discharge.
CONCLUSION
We herein report our experience of a splenic angiosarcoma whose multiple hepatic metastases responded well to the high-dose chemotherapy.
  • 3,612 View
  • 18 Download
Close layer
A case of carcinoma originating from aberrant breast tissue
Tae Joon Kim, Young Hong Lee, Ki Won Kim, Jong Ho Won, Dae Sik Hong, Hee Sook Park, So Young Jin, Dong Hwa Lee, Chul Moon
J Korean Cancer Assoc. 1993;25(3):450-454.
AbstractAbstract PDF
No abstract available.
  • 2,789 View
  • 12 Download
Close layer
A case of cardiac metastasis of hepatocelluar carcinoma through inferior vena cava
Chan Wook Park, Jin Ki Baik, Jong Ho Won, Dae Sik Hong, Hee Sook Park, Hye Kyung Lee
J Korean Cancer Assoc. 1993;25(3):445-449.
AbstractAbstract PDF
No abstract available.
  • 2,526 View
  • 12 Download
Close layer
The effect of chemotherapeutic agents on phagocytosis of polymorphonuclear leukocytes in patients with gastric cancer
Jong Ho Won, Dong Gib Ra, Jun Hee Woo, Dae Sik Hong, Hee Sook Park, Hi Bahl Lee
J Korean Cancer Assoc. 1992;24(2):249-255.
AbstractAbstract PDF
No abstract available.
  • 2,079 View
  • 13 Download
Close layer
A case of malignant lymphoma developed after gastric pseudolymphoma resection
Kee Won Kim, Chang Hyun Choi, Jong Ho Won, Dae Sik Hong, Hee Sook Park, So Young Jin, Dong Wha Lee
J Korean Cancer Assoc. 1992;24(1):187-193.
AbstractAbstract PDF
No abstract available.
  • 2,595 View
  • 13 Download
Close layer
Treatment with augmented TAD combination chemotherapy and consolidation in patient with acute myelogenous leukemia
Do Jin Kim, Jung Sil Whang, Jong Ho Won, Dae Sik Hong, Hee Sook Park, Won Bae Kim
J Korean Cancer Assoc. 1991;23(4):798-805.
AbstractAbstract PDF
No abstract available.
  • 2,520 View
  • 15 Download
Close layer
A clinical and electrophysiological studies of vincristine neurotoxicity
Joong Won Kim, Jong Ho Won, Dae Sik Hong, Hee Sook Park, Yang Gyun Lee
J Korean Cancer Assoc. 1991;23(2):252-258.
AbstractAbstract PDF
No abstract available.
  • 2,219 View
  • 14 Download
Close layer
Intracavitary Therapy with Bleomycin for The Treatment of Malignant Pleural and Pericardial Effusion
Hun Kwan Lim, Myung Lyel Lee, Jin Woo Jeon, Seong Gyu Park, Jong Ho Won, Seung Ho Baik, Dae Sik Hong, Hee Sook Park
J Korean Cancer Assoc. 1995;27(4):646-653.
AbstractAbstract PDF
Pleural effusions caused by malignancy occur commonly and are generally a manifestation of the advanced disease. Regardless of the underlying tumor type, mertality within 30 days has been reported to be as high as 50%. Respiratory insufficiency due to malignant pleural effusion often demands palliative management of the effusion. Malignant pericardial effusion is one of the most common causes of cardiac tamponade. Bleomycin and tetracycline have been widely used as sclerosing agents in malignant pleural effusion in North America and Europe. Bleomycin is less often used in the malignant pericardial effusion but is efficacious. Our study was begun to assess the effect and safety of bleomycin pleurodesis/pericardiodesis. Prospectively assigned twenty patients with malignant effusion(pleural effusion: 15, pericardial effusion; 5) to this therapy. Their age ranged from 19 to 69 years with a median of 47 years. Pri- mary sites were lung in 10, colon in 2, stomach, breast, uterine cervix, leg(sarcoma), mediastinum(malignant lymphoma), kidney in 1 each and unknown in 2(malignant melanoma and adenocarcinoma). The responses were categorized as objective response or failure. Twelve patients(70.5%) showed an objective response(complete response: 47% (8 cases), partial response: 23.5% (4 cases) out of 17 evaluable cases and the duration ranged from 5 to 78 weeks with a me- dian of 16 weeks. The response rates of malignant pericardial effusion and pleural effusion were 100/ and 61.5% respectively. Chest pain(10/17), and fever and/or chill(9/17) were the most common side effects. Other untoward effects included vomiting(4/17), anorexia(3/17), hypersensitivity(1/17), pyothorax(l/17). We conclude that bleomycin pleurodesis and pericardiodesis in malignant effusion can be performed safely and show good treatment effects, especially in maiignant pericardial effusion.
  • 3,835 View
  • 70 Download
Close layer
High - dose Chemotherapy with Hematopoietic Stem Cell Support for Malignant Lymphoma
Young Suk Park, Jung Ae Lee, Woo Sung Min, Seonyang Park, Jing Shin Lee, Hugh Chul Kim, Hoon Kook, Jong Ho Won, Dae Sik Hong, Hee Sook Park
J Korean Cancer Assoc. 1996;28(2):316-326.
AbstractAbstract PDF
Patients with intermediate or high-grade non-Hodgkin's lymphoma(NHL) have been reported a 40% to 70% cure rate when treated with conventional chemotherapy or radiotherapy. However, most of the patients who do not attain complete remission(CR) or who relapae after chemotherapy are incurable using conventional salvage therapies and these individuals have potential for cure with high-dose therapy with reinfusion of stem cells derived from bone marrow or peripheral blood. Between February 1993 and September 1995, 26 patients with aggressive, relapsed and/or refractory malignant lymphoma were treated with high-dose chemotherapy with either autologous peripheral blood stem cell(25 patients) or bone marrow(l patient) support in 7 university hospitals in Korea. The median age was 39 years(range, l7 to 69) and male to female ratio was 4.2: 1. The common histologic types were diffuse large cell(42%), immunoblastic type(15%) of non-Hodgkin's lymphoma. The rate of complete remission was 61%(14/23) and overall remission rate was 78%(18/ 23) for the patients with measurable disease. Three patients were treated as the consolidation therapy in the status of complete remission. The median duration of remission was not reached right now. The median survival time was 7.8 months for all patients(the median follow up time; 9 months). The median time to recovery to a neutrophil count more than 0.5 x 10(9)/L was 13 days(range, 8 to 43), and to 1 x 10(9)/L was 22 days(range, 8 to 53). The median time to recovery of platelet count more than 50 x l0(9)/L and 100 x 10(9)/L were 20 days(range, 8 to 45) and 21 days(ranae, ll to 60). Non-hematologic side effects were fever, nausea and vomiting, and liver toxicity. Two toxic deaths occurred due to cardiovascular disease, mainly congestive heart failure. Based on high complete remission rate and tolerable toxicity, high-dose chemotherapy with hematopietic stem cell support appears to be a promising treatment modality for the patients with aggressive, relapsed and/or refractory malignant lymphoma.
  • 2,751 View
  • 14 Download
Close layer
A Comparison of the Acute Antiemetic Effect of Granisetron with Combination of Metoclopramide , Dexamethasone and Lorazepam in Patients Receiving High
Won Yong Shin, Seong Gyu Park, Jin Woo Jeon, Jong Ho Won, Seung Ho Baik, Dae Sik Hong, Dae Sik Hong, Hee Sook Park
J Korean Cancer Assoc. 1996;28(3):582-589.
AbstractAbstract PDF
Granisetron, a 5-hydroxytryptamine3(5-HT3) receptor antagonist, is effective antiemetic agent in the control of cisplatin-induced emesis. We compared the efficacy and safety of granisetron with those of intravenous high-dose metoclopramide(1.5 mg/kg, four times) plus dexamethasone(10 mg i.v.) and lorazepam(2 mg i.v.)(MDL therapy) to control the acute emesis induced by high-dose cisplatin(>60mg/§³) treatment. Granisetron was injected in dose of 3 mg intravenously as recommended schedule for the prophylaxis of acute cisplatin-induced emesis. Granisetron was effective as MDL therapy for controlling of acute emesis. Of 25 granisetron-treated patients, 18(72%) were complete or major responders compared with 19/25(76%) patients who recieved the MDL therapy on first day of chemotherapy(P> 0.05). Also, in controlling of nausea, granisetron results were similar to MDL therapy. Side effects attributable to MDL group were sedation(60%)(P<0.01) and dizziness(20%)(P<0.05). In contrast to, headache(20%) of the granisetron group was higher than that of MDL group(P<0.05). Granisetron was effective as MDL therapy for controlling of the acute em esis and nausea induced by cisplatin. But, granisetron was more feasible and safer than MDL therapy.
  • 2,743 View
  • 15 Download
Close layer
Fibrinolytic Profiles in Malignant Pleural Effusion
Seung Ho Baik, Jin Woo Jeon, Jong Ho Won, Dae Sik Hong, Hee Sook Park
J Korean Cancer Assoc. 1996;28(4):705-710.
AbstractAbstract PDF
Plasminogen activators(PAs) and their inhibitors, plasminogen activator inhibitor-l(PAI-l) are known to play an important role in tumor invasion and metastasis. The differentiation of malignant pleural effusion(PE) from non-malignant pleural effusion is important for the management of a patient. Since malignant PE is a form of metastasis, and malignant cells are considered to be able to produce PAs or PAI-1, it seems reasonable to assume that PAa and PAI-1 in PE will be in somewhat different from that in non-malignant PE. We examined urokinase- type plasminogeo activator(uPA) and uPA receptor(uPAR) and tissue-type plasminogen activator(tPA), PAI-1 antigen using ELISA method and conventional laboratory tests and adenosine deaminase(ADA) in PEs. Levels of uPA, uPAR, tPA and PAI-1 were significantly increased in malignant and tuberculous PE than transudates(p<0.05) but not statistically significant between malignant and tuberculous PE. ADA in PE showed significantly increased in tuberculous PE than malignant PE and transudate(p<0.05). These data suggests that measurement of uPA, uPAR, tPA, PAI-1 antigen in addition to ADA could be helpful to differentiate malignant PE from tuberculous PE and transudate.
  • 2,592 View
  • 15 Download
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP